CBIOCrescent Biopharma, Inc.
$14.10+25% 1Y
$14.10
$8.9452 weeks$26.98
The financials
Crescent Biopharma, Inc. by the numbers
Crescent Biopharma, Inc. (CBIO) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $25M. For the full year FY2025, revenue was $11M and net income −$154M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | n/a |
| Operating income | −$26M | −$21M | n/a |
| Net income | −$25M | −$22M | n/a |